PCV164 PRESSURES FACED BY PEOPLE WHO CARE FOR SOMEBODY DIAGNOSED WITH A CARDIOVASCULAR CONDITION  by Hutton, J et al.
A344 Paris Abstracts
PCV163
GENDER-BASED DIFFERENCES IN HEALTH CARE COSTS AMONG ACS 
PATIENTS: AN APPLICATION OF THE BLINDER-OAXACA 
DECOMPOSITION
Zhao Z, Winget M
Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: Gender disparities exist in the treatment pathway for ACS patients, 
but the implications on costs have not been well established. This study investigates 
gender-based differences in health care costs among ACS patients. METHODS: A 
retrospective cohort study was conducted using the MarketScan claims database. A 
total of 11,649 patients (Female  3,601; Male  8,048), aged 18–65 years, hospital-
ized with a primary diagnosis of ACS between January 1, 2004 and December 31, 
2005 were identiﬁed. The Blinder-Oaxaca decomposition technique was performed to 
quantify the part of the gender differences in total health care costs that can be 
explained by differences in observable patient characteristics. The remaining difference 
was attributable to heterogeneous effects of these characteristics on health care costs. 
RESULTS: Male ACS patients had signiﬁcantly greater 1-year health care costs 
($49,552 vs. $41,838, p  0.0001) compared with females. Of the $7714 difference 
in costs, approximately two-thirds ($5300) can be explained by gender differences in 
demographic and clinical characteristics, while gender differences in effects of these 
characteristics accounted for approximately one-third ($2414) of the total differences. 
Out of the $5300 difference in costs, gender-based differences in comorbidity history 
and individual historical health care costs accounted for a $2380 reduction in gender 
costs discrepancy. In contrast, males had a higher rate of myocardial infarction and 
revascularization procedures during the initial hospitalization, which was associated 
with an increase in gender difference ($7680) in health care costs with revasculariza-
tion accounting for most of the difference ($6282). CONCLUSIONS: Differences in 
demographic and clinic characteristics between genders accounted for more than two-
thirds of differences in the health care costs. Differences in revascularization rates 
during initial hospitalization accounted for most of the explained gender costs 
differences.
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PRESSURES FACED BY PEOPLE WHO CARE FOR SOMEBODY 
DIAGNOSED WITH A CARDIOVASCULAR CONDITION
Hutton J, Beale S, Kruger J
York Health Economics Consortium, York, UK
OBJECTIVES: The Cardio and Vascular Coalition (CVC) commissioned YHEC to 
carry out a study to assess the opportunities and challenges facing cardiovascular 
disease in England (2008–2018). Part of this study involved assessing the pressures 
that face people who care for somebody diagnosed with a cardiovascular condition. 
METHODS: A questionnaire, developed with input from the CVC, was piloted before 
being distributed by CVC organisations to 825 of their members. Data from 176 
questionnaires were analysed (giving a response rate of 21%). Some caution should 
be used when generalising ﬁndings as all respondents were members of a CVC organi-
sation. RESULTS: Most respondents were the spouse or partner of the person cared 
for (92%), female (80%), white (96%), retired (70%) and had been caring for some-
body who had been diagnosed for more than 5 years (75%). Just over a third of 
respondents (34%) said that they felt that their health had deteriorated as a result of 
being a carer. A number of different categories of people provided support to carers. 
Support was provided on most occasions by Family/friends (31%) and GPs (28%), 
and to a lesser extent by Condition Speciﬁc Support Groups (15%), Other Professional 
Carers (15%) and Other Categories (13%). Support to carers was provided ‘in Current 
situation’ (40%) ‘After Diagnosis’ (36%) and ‘After most recent hospital episode’ 
(24%). The most frequently cited ways that carers felt that their life could be made 
easier were through provision of more health care and professional support, informa-
tion and practical help with every day life. CONCLUSIONS: More attention should 
be given to the needs of those caring for people with CVD. Carers bear signiﬁcant 
economic and psychological burdens, in many cases without adequate information 
and support. Their role will become increasingly important as more people survive 
acute CVD events and live with heart disease.
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CHANGES IN THE COST-EFFICACY OF STATINS IN SPAIN AFTER THE 
INTRODUCTION OF GENERICS AND REFERENCE PRICES
Plans-Rubió P
General Directorate of Public Health, Barcelona, Spain
OBJECTIVES: To assess the effect of generics and reference prices for simvastatin, 
lovastatin and pravastatin, introduced since 2003, on the cost-efﬁcacy of statins in 
Spain. METHODS: The effect was assessed determing the cost-efﬁcacy of atorvastatin 
10–80 mg/day, simvastatin and pravastatin 10–40 mg/day and lovastatin and ﬂuvas-
tatin 20–80 mg/day in terms of annual treatment costs per percentage of LDL-
 cholesterol reduction in 2003 and 2008. Annual treatment costs included medication, 
control measures and adverse side affects. Efﬁcacy of statins to reduce LDL-cholesterol 
was determined developing a meta-analysis including long-term clinical trials pub-
lished between 1993 and 2005. Average and incremental cost-efﬁcacy ratios were 
calculated to assess the efﬁciency of statin therapies and to develop recommendations 
for cholesterol-lowering therapies based on cost-efﬁcacy. RESULTS: Efﬁcacy of statin 
therapies in terms of percentage of LDL-cholesterol reduction ranged from 19 % for 
pravastatin 10 mg/day to 54 % for atorvastatin 80 mg/day. In 2008, cost-efﬁcacy 
ratios in terms of cost per % of LDL-cholesterol reduced were a8–10 for simvastatin, 
a11–14 for lovastatin, a11–37 for atorvastatin, a14–23 for ﬂuvastatin and a18–31 
for pravastatin. Cost-efﬁcacy ratios decreased between 2003 and 2008 by 4–7 % for 
atorvastatin, 33–51 % for simvastatin (p  0.05), 24–38 % for lovastatin (p  0.05), 
4–5 % for ﬂuvastatin and 16–23 % for pravastatin (p  0.05). Based on cost-efﬁcacy 
in 2008, atorvastatin 20–80 mg/day should be the ﬁrst election therapy in patients 
requiring a LDL-cholesterol reduction of  41 %, simvastatin 40 mg/day or atorvas-
tatin 10 mg/day in those requiring a reduction of 35–41 % and simvastatin 10–20 mg/
day in those requiring a reduction  35 %. CONCLUSIONS: Generics and reference 
prices have driven down statins’ prices between 2003 and 2008, increasing the cost-
efﬁcacy of all statins. Atorvastatin should be the ﬁrst election drug in patients requiring 
a high LDL-cholesterol reduction and simvastatin in patients requiring a LDL-
 cholesterol reduction of less than 35 %.
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ADENOSINE-STRESS CARDIAC MAGNETIC RESONANCE IMAGING IN 
SUSPECTED CORONARY ARTERY DISEASE: A NET COST ANALYSIS & 
REIMBURSEMENT IMPLICATIONS
Pilz G1, Patel PA2, Fell U3, Rizzo JA4, Fang H5, Gunnarsson C6, Graw M1, Hoeﬂing B1
1Clinic Agatharied, University of Munich, Hausham, Germany, 2GE Healthcare, Barrington, IL, 
USA, 3GE Healthcare, Munich, Germany, 4Stony Brook University, Stony Brook, NY, USA, 
5University of Colorado, Aurora, CO, USA, 6S2 Statistical Solutions, Inc, Cincinnati, OH, USA
OBJECTIVES: To investigate whether the use of cardiac magnetic resonance imagin-
ing (CMR) to diagnose cardiac risk saves costs by leading to reductions in referrals 
for cardiac catheterization. METHODS: Two hundred and eighteen subjects were 
matched to a prior sample in which CMR was demonstrated to reliably stratify 
patients regarding their risk of major cardiac events. Propensity scoring methods were 
used to match on comorbidity proﬁles, demographics, coronary artery disease (CAD)-
related clinical presentation, and CAD risk as measured by their Morise scores. The 
matched sample included adult subjects with suspected coronary artery disease who 
were evaluated by stress CMR. We identiﬁed the proportion of patients who were 
able to avoid cardiac catheterization based upon the results of their CMR tests. Given 
this information, and data on the costs of cardiac catheterization and CMR tests, a 
net cost analysis was performed. RESULTS: CMR use substantially reduces the need 
for cardiac catheterization by 62.4%. In countries like Germany CMR is not yet 
reimbursed. Assuming CATH costs of a631, the breakeven-level for CMR costs at 
which it is cost neutral is a393. These results were robust in sensitivity analysis. Cost 
savings are greatest for patients with lowest risk of CAD as measured by their baseline 
Morise scores. However, cost savings are likely for all Morise sub groups examined, 
with the exception of patients at the highest risk of CAD as measured by their Morise 
score. CONCLUSIONS: CMR is a safe and cost effective approach to evaluating 
patients with suspected CAD. Even at reimbursement levels up to a390, the use of 
CMR as a gatekeeper saves money.
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A CLUSTER RANDOMIZED CONTROLLED TRIAL TO EVALUATE AN 
AMBULATORY PRIMARY CARE MANAGEMENT PROGRAM FOR 
PATIENTS WITH DYSLIPIDEMIA: TEAM STUDY
Lalonde L1, Villeneuve J1, Genest J2, Blais L1, Vanier MC1, Lamarre D1, Fredette MJ3, 
Perreault S1, Hudon E4, Djamal B5
1University of Montreal, Montreal, QC, Canada, 2McGill University Health Center, Royal-
Victoria Hospital, Montreal, QC, Canada, 3HEC, Montreal, QC, Canada, 4Centre de Santé et 
Services Sociaux de Laval, Laval, QC, Canada, 5Centre de santé et de services sociaux de 
Laval, Laval, QC, Canada
OBJECTIVES: Evaluate the efﬁcacy of family physician-community pharmacist 
 collaborative care (PPCC) in which pharmacists are responsible for titrating lipid-
lowering pharmacotherapy. METHODS: 15 clusters comprising 77 physicians and 
108 pharmacists were randomly assigned to the PPCC or the usual care (UC) group. 
A total of 108 PPCC and 117 UC patients were followed for 12 months. PPCC phar-
macists provided counselling; requested laboratory tests; monitored effectiveness, 
safety, and adherence to treatment; and adjusted medication dosage. Change in 
low-density lipoprotein cholesterol (LDL-C) level (primary outcome), proportion of 
patients reaching their target lipid levels and changes in other risk factors were assessed 
at month 12. RESULTS: At baseline, PPCC patients had higher LDL-C (3.5 versus 
3.2 mmol/L;p  0.05). During the study, they were less likely to receive high-potency 
statin (11.1% versus 39.7%), had more health-professional visits and laboratory tests, 
were more likely to have their lipid-lowering treatment changed, and to report lifestyle 
changes. At 12 months, the difference in the crude and the adjusted mean change in 
LDL-C between the PPCC and the UC groups was equal to 0.2 mmol/L (95%CI: 0.3 
to 0.1) and 0.04 (95%CI: 0.3 to 0.2), respectively. The crude and the adjusted 
relative risk of achieving lipid targets were equal to 1.10 (95%CI: 0.95 to 1.26) and 
1.16 (1.01 to 1.32), respectively. CONCLUSIONS: Collaborative practice can be 
implemented in primary care. Among patients with modest dyslipidemia, this study 
provides no evidence of a signiﬁcant clinical impact on lipid control.
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COMMUNITY PHARMACY DISPENSING OF PRESCRIPTION  
MEDICINE SAMPLE PACKS—CHANGING THE BUSINESS OF  
MEDICINE INITIATION?
Kyle GJ, Nissen LM, Tett SE
The University of Queensland, St Lucia, QLD, Australia
OBJECTIVES: To pilot and ascertain the viability of an alternative supply model for 
free sample (starter) packs of prescription medicines involving community pharma-
cists. METHODS: General practitioners (GPs) recruited patients (purposive sampling) 
